FibroGen Inc
NASDAQ:FGEN

Watchlist Manager
FibroGen Inc Logo
FibroGen Inc
NASDAQ:FGEN
Watchlist
Price: 8.38 USD -3.68% Market Closed
Market Cap: 33.9m USD

During the last 3 months FibroGen Inc insiders bought 33.7k USD , and have not sold any shares. The stock price has dropped by 29% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Wettig Thane , who bought 24.6k USD worth of FGEN shares.

Last Transactions:
Wettig Thane
$+24.6k
Wettig Thane
Chief Executive Officer
$+9.2k
Schoeneck James A
$+119.5k
Wettig Thane
$+2k
Schoeneck James A
$+681.6
Schoeneck James A
$+3.5k
Adib Deyaa
$+1k
Wettig Thane
$+3.8k
Henderson Jeffrey William
$-82.4
Henderson Jeffrey William
$-152.8
Henderson Jeffrey William
$-215.2
Conterno Enrique A
$-210
Chung Christine
$-3.5k
Chung Christine
$-4.4k
Brennan Aoife
$-1.3k
Cravatt Benjamin
$-1.2k
Edwards Jeffrey L
$-2.2k
Blaug Suzanne
$-2.2k
Ho Maykin
$-1.5k
Henderson Jeffrey William
$-1.3k
Schoeneck James A
$-5.1k
Wettig Thane
$-323.7
Graham Juan
$-711.9
Chung Christine
$-919.9
Eisner Mark
$-1.4k
Conterno Enrique A
$-1.9k
Wettig Thane
$-323.7
Eisner Mark
$-828.5
Conterno Enrique A
$-1.5k
Eisner Mark
$-6.9k
Chung Christine
$-5k
Wettig Thane
$-673.6
View All Transactions

During the last 3 months FibroGen Inc insiders bought 33.7k USD , and have not sold any shares. The stock price has dropped by 29% over this period (open performance analysis).

The last transaction was made on Nov 17, 2025 by Wettig Thane , who bought 24.6k USD worth of FGEN shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
1
33.7k USD
3-6
months
1
119.5k USD
6-9
months
2
6.2k USD
9-12
months
No Insider Transactions
0
0 USD

FibroGen Inc
Insider Trading Chart

FibroGen Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

FibroGen Inc
Last Insider Transactions

Global
Insiders Monitor

FibroGen Inc
Glance View

Market Cap
33.9m USD
Industry
Biotechnology

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 566 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The firm is also enrolling patients in its two Phase III trials of pamrevlumab patients.

FGEN Intrinsic Value
HIDDEN
Show

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top